Weight Loss Medical Director in Arizona
Specialty Medical Director services for Arizona medical weight-loss clinics and GLP-1 programs prescribing semaglutide, tirzepatide, and compounded weight-management medications. Prescriptive authority, GLP-1 titration protocols, patient eligibility screening, side-effect management, compounded-pharmacy coordination, and RN delegation — the full clinical framework a weight-loss clinic needs to operate legally and safely in Arizona. Delivered by Naomi Fayzulayev, FNP-C, an AZ-licensed, full-practice-authority Family Nurse Practitioner.
4731 E Union Hills Dr, Suite 114
Phoenix, AZ 85050
Why GLP-1 directorship demands more than a signature.
The GLP-1 weight-loss boom is real — and so is the regulatory scrutiny that follows it. Semaglutide and tirzepatide are prescription medications with a defined side-effect profile, real contraindications, and an evolving compliance landscape around compounded formulations. A weight-loss clinic that treats directorship as a name on paperwork is exactly the kind of practice that draws a Board of Nursing or Board of Pharmacy inquiry when something goes wrong.
A defensible GLP-1 directorship means the Medical Director actually owns the clinical layer: the eligibility criteria that keep unsuitable patients out, the titration protocol that manages nausea and GI effects, the red-flag screening for pancreatitis and gallbladder disease, the personal and family history screening for medullary thyroid carcinoma and MEN2, and the documentation that holds up if a patient has an adverse event.
Beso Provider Hub provides that full framework. As an actively-practicing FNP-C with full prescriptive authority in Arizona, Naomi Fayzulayev prescribes and manages weight-management protocols — so the standing orders your clinic runs on are clinically current, not copied from a template. The compounded-GLP-1 regulatory landscape in particular is shifting quickly; protocols need a director who tracks FDA and state Board of Pharmacy guidance, not one who set them up once and disappeared.
For context on retainer ranges across specialties, see our 2026 Arizona MD Cost Benchmark. If your clinic also runs IV therapy or hormones alongside weight loss, those layer into a single combined engagement — see IV Therapy Medical Director.
Weight-loss programs we build the framework for.
Every medication and program on your menu gets its own written protocol — eligibility, titration, monitoring, and adverse-event response. Below is the modern medical weight-loss menu.
The screening & safety protocols that matter most.
GLP-1 programs live or die on patient selection and side-effect management. Every one of these is built and maintained as part of the engagement.
What’s included for Arizona weight-loss clinics.
Every weight-loss MD engagement includes the following. The GLP-1 protocol library and eligibility framework are the deliverables that separate real directorship from paperwork.
Compounded GLP-1 in Arizona —
503A, 503B & the FDA shortage-list reality
Semaglutide came off the FDA drug shortage list on February 21, 2025. Tirzepatide came off on December 19, 2024. That single regulatory shift ended blanket 503A permission for compounding these medications from bulk API and pushed every Arizona practice offering compounded GLP-1 to reassess sourcing and documentation. This is the single hottest compliance question in weight-loss medicine in 2026, and Beso Provider Hub structures directorship around it directly.
503A vs. 503B — the practical distinction
A 503A pharmacy compounds patient-specific prescriptions for individual patients under a doctor-patient relationship. A 503B outsourcing facility is FDA-registered, follows cGMP standards, and can compound in bulk for provider offices without patient-specific prescriptions. Post-shortage, the compliant path for most Arizona weight-loss practices is documented 503B sourcing (or genuinely patient-specific 503A prescribing tied to a documented clinical rationale) — not the bulk 503A pipeline many practices ran during the shortage.
What the Arizona State Board of Pharmacy watches for
The AZ State Board of Pharmacy inspects and enforces sourcing, and complaint-driven audits go straight to the practice’s pharmacy documentation. The records that keep a practice out of trouble:
- Pharmacy licensure verification (FDA registration for 503B; state-board license for 503A)
- Certificates of analysis for each lot received
- Patient-specific prescriptions or documented office-use orders
- Clinical rationale for compounding (allergy, dose, or excipient documentation for 503A)
- Chain-of-custody and storage records
How Beso structures compounded-GLP-1 directorship
Naomi vets each source pharmacy against the current AZ Board of Pharmacy and FDA landscape, documents the sourcing rationale in writing, aligns prescribing protocols to what your specific pharmacy actually compounds, and updates the framework when the regulatory landscape shifts — which, in 2026, it does. This is exactly the difference between a directorship engineered around the actual product your patients receive and a directorship that signs a template and hopes nothing changes.
Good-Faith Exam (GFE) protocols —
where AZ actually requires them.
Every Arizona weight-loss practice offering semaglutide, tirzepatide, or compounded metabolic peptides is subject to a specific documentation standard: the Arizona State Board of Nursing’s 2025 Advisory Opinion on Medical Aesthetic Procedures, which extends to Level II and Level III prescription treatments. The Advisory Opinion is technically an interpretation but operationally binding — ASBN reviewers ask for the documentation it requires when a complaint or audit lands.
What the Advisory Opinion requires
- An initial face-to-face good-faith exam of the patient before treatment
- A written provider order issued before the medication is administered or dispensed
- Standing orders permitted, but only tied to a documented GFE
- The GFE is repeatable annually or on any material change in the patient’s health history
Who can issue the written provider order for GLP-1?
Under A.R.S. § 32-1606, an Arizona NP with full practice authority holds independent prescriptive authority and can issue the written provider order — no physician co-signature required. For NP-owned weight-loss clinics, this is a structural advantage over restricted states. If your clinic uses RN, PA, or telehealth support staff to administer weight-loss medications, the NP director (or a physician director) must issue and document the order for each patient. See our guide to NP directorship in Arizona for the full picture.
The GFE workflow Beso builds for Arizona clinics
Every Beso weight-loss directorship engagement includes a documented GFE workflow: intake screening, initial in-person or synchronous telehealth exam, baseline labs (A1C, TSH, lipid panel, CMP), eligibility screening against contraindications, the written provider order tying the GFE to a specific patient, and the annual re-exam trigger. This is the documentation ASBN reviews first when a complaint hits a weight-loss clinic.
The three watchdogs that matter for Arizona GLP-1 clinics right now.
Semaglutide off the shortage list Feb 21, 2025. Tirzepatide off Dec 19, 2024. Bulk 503A compounding without patient-specific rationale is no longer defensible. Warning letters and enforcement have followed.
Level II/III prescription treatments (which includes GLP-1) require a documented good-faith exam and written provider order. Operationally binding for every AZ weight-loss clinic; audited on complaint.
Inspects 503A patient-specific rationale, 503B outsourcing-facility documentation, certificates of analysis, and chain-of-custody. Enforcement is complaint-driven and targets sourcing paperwork first.
Beso directorship tracks all three continuously — because in 2026, this landscape moves quarterly.
You get Naomi — not a matched physician you’ve never spoken to.
Naomi prescribes and titrates GLP-1 protocols at Beso Wellness & Beauty weekly. Your protocol library is the one she uses on her own patients — not a template a broker retrieved.
Shortage list, warning letters, DEA scheduling shifts — tracked continuously. Your practice gets an updated framework when the regulatory environment changes, not a stale template.
Pancreatitis red flag on an intake at 2pm Wednesday. A patient with a bulimia history asking for higher-dose. Real clinical questions get a real answer, not a ticket queue.
Naomi knows the AZ Board of Nursing Advisory Opinion, the AZ Board of Pharmacy audit pattern, and the DEA registration reality — not 50 states of generic compliance.
“We launched our weight-loss program in three weeks with Beso as director. Naomi rewrote our intake, titration, and pancreatitis screening from her own clinic protocols, vetted our compounding pharmacy against current Board of Pharmacy rules, and structured GFE documentation that matches the 2025 Advisory Opinion exactly. When the FDA shortage-list change happened, she updated our sourcing framework the same week.”